| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
topoisomerase II alpha
Human DNA topoisomerase IIα (htIIα). Topoisomerase IIα is a nuclear enzyme that catalyzes the ATP-dependent passage of one DNA double helix through another, relieving DNA supercoiling and resolving catenated DNA intermediates. It is essential for DNA replication, chromosome condensation, and sister chromatid segregation during mitosis. Topoisomerase IIα is a validated target for anticancer drugs such as etoposide and doxorubicin. |
|---|---|
| ln Vitro |
Topoisomerase IIα-IN-8 is a weak inhibitor of human DNA topoisomerase IIα with an IC50 of 462 ± 38.0 μM. The compound's weak inhibitory activity suggests limited efficacy in cellular assays. It may serve as a reference compound or chemical probe for studying topoisomerase IIα inhibition, but its potency is significantly lower than clinically approved topoisomerase II inhibitors.
|
| ln Vivo |
Detailed in vivo activity data for Topoisomerase IIα-IN-8 are not available in the literature. As a weak inhibitor with an IC50 in the high micromolar range, it is unlikely to demonstrate significant in vivo efficacy. It is used primarily as a research tool for in vitro studies of topoisomerase IIα inhibition. Further studies would be needed to determine its in vivo activity.
|
| Enzyme Assay |
In vitro enzyme inhibition assays are performed using purified human DNA topoisomerase IIα incubated with varying concentrations of Topoisomerase IIα-IN-8 and a DNA substrate (e.g., supercoiled pBR322 plasmid DNA). The reaction is carried out in ATP-containing buffer at 37°C. DNA relaxation or decatenation activity is measured by agarose gel electrophoresis, and IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Topoisomerase IIα-IN-8 is not typically used in cell-based assays due to its weak potency. If used, cancer cell lines are treated with the compound at high micromolar concentrations, and cell viability is assessed using standard assays such as MTT or CCK-8. DNA damage markers (e.g., γ-H2AX) may be measured by Western blotting to assess topoisomerase II inhibition.
|
| Animal Protocol |
In vivo animal studies for Topoisomerase IIα-IN-8 have not been reported. If used, xenograft mouse models would be administered the compound via oral or intraperitoneal routes, and tumor growth inhibition would be assessed. However, due to its weak potency, significant in vivo efficacy is unlikely.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Topoisomerase IIα-IN-8 have not been extensively characterized. The compound is soluble in DMSO and has a molecular weight of 314.32. It is typically stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year. Detailed PK data (Cmax, Tmax, AUC, t1/2) are not available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Topoisomerase IIα-IN-8 are not available. As a weak topoisomerase II inhibitor, its toxicity profile is expected to be less severe than potent topoisomerase II poisons such as etoposide. However, standard laboratory safety practices should be followed when handling the compound. It is not intended for human use.
|
| References | |
| Additional Infomation |
Topoisomerase IIα-IN-8 is a research-grade compound used for studying human DNA topoisomerase IIα inhibition. CAS: 1251578-67-2. Molecular formula: C15H15FN6O, molecular weight: 314.32. Synonyms: N-(4-fluorophenyl)-6-morpholino-9H-purin-2-amine. It is a weak inhibitor with an IC50 of 462 μM. For research use only, not for human therapeutic use.
|
| Molecular Formula |
C15H15FN6O
|
|---|---|
| Molecular Weight |
314.32
|
| Exact Mass |
314.129
|
| CAS # |
1251578-67-2
|
| PubChem CID |
52417176
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
637.4±65.0 °C at 760 mmHg
|
| Flash Point |
339.3±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.709
|
| LogP |
1.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
388
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1COCCN1C2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)F
|
| InChi Key |
KPXPXKOSEYWROL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H15FN6O/c16-10-1-3-11(4-2-10)19-15-20-13-12(17-9-18-13)14(21-15)22-5-7-23-8-6-22/h1-4,9H,5-8H2,(H2,17,18,19,20,21)
|
| Chemical Name |
N-(4-fluorophenyl)-6-morpholin-4-yl-7H-purin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1815 mL | 15.9074 mL | 31.8147 mL | |
| 5 mM | 0.6363 mL | 3.1815 mL | 6.3629 mL | |
| 10 mM | 0.3181 mL | 1.5907 mL | 3.1815 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
